Biogen Inc. (BIIB) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
BIIB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BIIB Revenue Analysis (2014–2025)
As of March 1, 2026, Biogen Inc. (BIIB) generated trailing twelve-month (TTM) revenue of $9.81 billion, reflecting moderate decline in growth of -7.1% year-over-year. The most recent quarter (Q4 2025) recorded $2.28 billion in revenue, down 7.1% sequentially.
Looking at the longer-term picture, BIIB's 5-year compound annual growth rate (CAGR) stands at -6.1%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $14.38 billion in 2019.
Revenue diversification analysis shows BIIB's business is primarily driven by MS Product Revenues (42%), TYSABRI product (17%), and SPINRAZA (16%).
When compared to Healthcare sector peers including ABBV (+7.4% YoY), AMGN (+9.9% YoY), and GILD (+2.4% YoY), BIIB has underperformed the peer group in terms of revenue growth. Compare BIIB vs ABBV →
Peer Comparison
Compare BIIB's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BIIBCurrent | $9.8B | -7.1% | -6.1% | 19.1% | |
| ABBV | $56.3B | +7.4% | +11.1% | 16.2% | |
| AMGN | $36.8B | +9.9% | +7.6% | 40.5% | |
| GILD | $28.8B | +2.4% | +5.1% | 5.8% | |
| NVO | $297.2B | +2.3% | +18.5% | 41.4% | |
| SCLX | $57M | -26.8% | - | -147.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9.81B | +1.4% | $6.91B | 70.5% | $1.88B | 19.1% |
| 2024 | $9.68B | -1.6% | $7.37B | 76.1% | $2.49B | 25.7% |
| 2023 | $9.84B | -3.3% | $7.30B | 74.2% | $2.10B | 21.3% |
| 2022 | $10.17B | -7.4% | $7.90B | 77.6% | $2.89B | 28.4% |
| 2021 | $10.98B | -18.3% | $8.87B | 80.8% | $2.79B | 25.4% |
| 2020 | $13.44B | -6.5% | $11.64B | 86.6% | $4.59B | 34.2% |
| 2019 | $14.38B | +6.9% | $12.42B | 86.4% | $7.04B | 49.0% |
| 2018 | $13.45B | +9.6% | $11.64B | 86.5% | $5.89B | 43.8% |
| 2017 | $12.27B | +7.2% | $10.64B | 86.7% | $5.35B | 43.6% |
| 2016 | $11.45B | +6.4% | $10.02B | 87.5% | $5.15B | 45.0% |
See BIIB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIIB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BIIB vs AGIO
See how BIIB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BIIB's revenue growth accelerating or slowing?
BIIB revenue declined -7.1% year-over-year, contrasting with the 5-year CAGR of -6.1%. TTM revenue fell to $9.8B. This reverses the prior growth trend.
What is BIIB's long-term revenue growth rate?
Biogen Inc.'s 5-year revenue CAGR of -6.1% reflects the variable expansion pattern. Current YoY growth of -7.1% is below this long-term average.
How is BIIB's revenue distributed by segment?
BIIB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.